Urinary 6-sulfatoxymelatonin excretion and galectin-3 plasma level in patients with osteoarthritis

Abstract

Melatonin and galectin-3 are considered as factors in the development of immune-inflammatory and destructive changes in joints. To study the excretion of 6-sulfatexymelatonin and galectin-3 level in the blood and evaluate their association with the clinical manifestation and life quality in patients with osteoarthritis (OA) were investigated 141 patients with OA of knee joints (76.6% women), aged 58.4±7.91 years, duration of the disease 10.5±6.50 years. It was established in patients with OA a decrease in 6-SMT excretion (mean 25.3 vs 38.8 ng/mg creatinine in control). 6-SMT excretion correlated with age and was more significant in patients with knee +hip OA (mean 26.5 vs 23.0 ng/mg creatinine in patients with OA of the knee only). Lower levels of 6-SMT excretion associated with higher pain and with lower quality of life. Lower levels of melatonin and higher of galectin-3 were associated with higher WOMAC index and poorer quality of life in patients with OA. This association may reflect possible pathogenic role of melatonin and galectin-3 in OA.